Home | Clinical Trials

FDA Approved Drugs » Therapeutic Areas

View By:Year | Company | Conditions | Therapeutic Areas | Drug Names

FDA Approved Drugs by Therapeutic Area

Search by therapeutic area for drugs approved by the Food and Drug Administration (FDA) for sale in the United States. Click on an area below to view the complete list of drugs in that category or review descriptions for our therapeutic area list to assist you in your search.

Find out more about the types of drugs included in this listing.

FDA Approved Drugs for Nephrology

Drugs Approved in 2014

Ferric citrate; Keryx Biopharma; For the treatment of hyperphosphatemia in patients with chronic kidney disease, Approved September 2014

Drugs Approved in 2013

Injectafer (ferric carboxymaltose injection); Luitpold Pharmaceuticals; For the treatment of iron deficiency anemia, Approved July 2013

Procysbi (cysteamine bitartrate); Raptor Pharmaceuticals; For the management of nephropathic cystinosis, Approved May 2013

Drugs Approved in 2012

Afinitor (everolimus); Novartis; For the treatment of renal angiomyolipoma associated with tuberous sclerosis complex, Approved April 2012

Inlyta (axitinib); Pfizer; For the treatment of advanced renal cell carcinoma, Approved January 2012

Myrbetriq (mirabegron); Astellas Pharma US, Inc; For the treatment of overactive bladder, Approved June 2012

Omontys (peginesatide); Affymax; For the treatment of anemia due to chronic kidney disease, Approved March 2012

Stendra (avanafil); Vivus; For the treatment of erectile dysfunction, Approved April 2012

Stivarga (regorafenib); Bayer HealthCare Pharmaceuticals; For the treatment of previously treated patients with metastatic colorectal cancer, Approved September 2012

Voraxaze (glucarpidase); BTG International; For the treatment of toxic plasma methotrexate concentrations in patients with impaired renal function, Approved January 2012

Drugs Approved in 2011

Anturol (oxybutynin) Gel; Antares Pharma; For the treatment of overactive bladder, Approved December 2011

Nulojix (belatacept); Bristol-Myers Squibb; For the prevention of organ rejection following kidney transplant, Approved June 2011

Soliris (eculizumab); Alexion; For the treatment of atypical hemolytic uremic syndrome, Approved September 2011

Drugs Approved in 2010

Carbaglu (carglumic acid); Recordati; For the treatment of hyperammonemia, Approved March 2010

Jalyn (dutasteride + tamsulosin); GlaxoSmithKline; For the treatment of benign prostatic hyperplasia, Approved June 2010

Jevtana (cabazitaxel); sanofi aventis; For the treatment of prostate cancer, Approved June 2010

Provenge (sipuleucel-T); Dendreon; For the treatment of hormone refractory prostate cancer, Approved May 2010

Xifaxan (rifaximin); Salix Pharmaceuticals; For the treatment of hepatic encephalopathy, Approved March 2010

Zortress (everolimus); Novartis; For the prevention of organ rejection following kidney transplant, Approved May 2010

Drugs Approved in 2009

Afinitor (everolimus); Novartis; For the treatment of renal cell carcinoma, Approved March 2009

Avastin (bevacizumab); Genentech; For the treatment of renal cell carcinoma, Approved July 2009

Feraheme (ferumoxytol); AMAG; For the treatment of iron deficiency anemia associated with chronic kidney disease, Approved June 2009

Gelnique (oxybutynin chloride); Watson Pharmaceuticals; For the treatment of overactive bladder, Approved January 2009

Votrient (pazopanib); GlaxoSmithKline; For the treatment of renal cell carcinoma, Approved October of 2009

Drugs Approved in 2008

Degarelix (degarelix for injection); Ferring Pharmaceuticals; For the treatment of prostate cancer, Approved December of 2008

Toviaz (fesoterodine fumarate); Pfizer; For the treatment of overactive bladder, Approved October 2008

Drugs Approved in 2007

Doribax (doripenem); Johnson & Johnson; For the treatment of intra-abdominal infections and urinary tract infections, Approved October 2007

Mircera (methoxy polyethylene glycol-epoetin beta); Roche; For the treatment of anemia associated with chronic renal failure, Approved November 2007

Renvela (sevelamer carbonate); Genzyme; For the control of serum phosphorus in patients with chronic kidney disease on dialysis, Approved October 2007

Torisel (temsirolimus); Wyeth; For the treatment of renal cell carcinoma, Approved May 2007

Drugs Approved in 2005

Vaprisol (conivaptan); Astellas Pharma US, Inc; For the treatment of euvolemic hyponatremia, Approved December 2005

Drugs Approved in 2004

Fosrenol, lanthanum carbonate; Shire Pharmaceuticals; For the treatment of hyperphosphatemia related to kidney dysfunction, Approved October, 2004

Sanctura (trospium chloride); Indevus Pharmaceuticals; For the treatment of overactive bladder with symptoms of urge urinary incontinence, Approved May, 2004

Sensipar (cinacalcet); Amgen; For the treatment of secondary hyperparathyroidism and hypercalcemia in parathyroid carcinoma patients, Approved March 2004

Vesicare (solifenacin succinate); Yamanouchi, GlaxoSmithKline; For the treatment of overactive bladder with symptoms of urge urinary incontinence, Approved November, 2004

Drugs Approved in 2003

Fabrazyme (agalsidase beta); Genzyme; For the treatment of Fabry disease in adult patients, Approved April 2003

Oxytrol (oxybutynin transdermal system); Watson Pharmaceuticals; For the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency., Approved March 2003

UroXatral (alfuzosin HCl extended-release tablets); Sanofi-aventis; For the treatment of of the signs and symptoms of benign prostatic hyperplasia, Approved June 2003

Drugs Approved in 2002

Eligard (leuprolide acetate); Atrix Laboratories; For the palliative treatment of advanced prostate cancer, Approved January 2002

Mesnex; Bristol-Myers Squibb, Baxter Healthcare; Oral tablet to inhibit the hemorrhagic cystitis induced by Ifex (ifosfamide), Approved March 2002

Drugs Approved in 2001

Dutasteride; GlaxoSmithKline; For the treatment of symptomatic benign prostatic hyperplasia, Approved November 2001

Invanz; Merck; Once-daily injectable treatment for bacterial infections, Approved November 2001

PhosLo; Braintree Laboratories; Oral capsules and gelcaps for the control of hyperphosphatemia in end stage renal failure, Approved April 2001

Trelstar LA (triptorelin pamoate); Debiopharm; Intramuscular injection for the treatment of advanced stage prostate cancer, Approved June 2001

Drugs Approved in 2000

Cefazolin and Dextrose USP; B Braun Medical; Respiratory tract infections, Approved July 2000

Detrol LA (tolterodine tartrate); Pharmacia & Upjohn; For the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency, Approved December 2000

Hectorol (Doxercalciferol) Injection; Bone Care International; To reduce iPTH levels in management of secondary hyperparathyroidism in patients undergoing chronic renal dialysis, Approved April 2000

Rapamune (sirolimus) Tablets; Wyeth; For treatment of kidney rejection, Approved August 2000

Renagel (sevelamer hydrochloride); GelTex Pharmaceuticals; For the reduction of serum phosphorus in patients with end-stage renal disease (ESRD), Approved July 2000

Renagel (sevelamer hydrochloride); Genzyme; For the control of serum phosphorus in patients with chronic kidney disease on dialysis, Approved July of 2000

Trelstar Depot (triptorelin pamoate); Debio Rechereche Pharmaceutique, Target Research Associates; For the palliative treatment of advanced prostate cancer, Approved June 2000

Venofer (iron sucrose injection); Luitpold Pharmaceuticals; For the treatment of iron deficiency anemia in patients undergoing chronic hemodialysis, Approved November 2000

Viadur (leuprolide acetate implant); Alza; For pain relief in men with advanced prostate cancer, Approved March 2000

Drugs Approved in 1999

Ditropan XL (oxybutynin chloride); Alza; Treatment for overactive bladder, Approved June 1999

Levaquin; RW Johnson; Treatment for urinary tract infection, Approved July 1999

Tequin; Bristol-Myers Squibb; Tequin (Injectable and Tablet), December, 1999

Drugs Approved in 1998

Detrol (tolterodine tartrate); Pharmacia & Upjohn; Treatment for an overactive bladder, Approved March 1998

Ditropan XL (oxybutynin chloride); Alza; Treatment for and Overactive Bladder, Approved December 1998

Proscar; Merck; Treatment for complication relating to benign prostatic hyperplasia (BPH), Approved April 1998

RenaGelRenagel (sevelamer hydrochloride); GelTex Pharmaceuticals; Treatment for Renal Disease, Approved November 1998

Simulect; Novartis; Treatment for acute organ transplant rejection, Approved May 1998

Zemplar; Abbott Laboratories; Treatment of secondary hyperparathyroidism associated with chronic renal failure, Approved April 1998

Drugs Approved in 1997

EDEX; Schwarz Pharma; Treatment for erectile dysfunction, Approved June 1997

FLOMAX; Boehringer Ingelheim; Treatment for benign prostatic hypertrophy (BPH), Approved October 1997

Interstim Continence Control Therapy; Medtronic; Treatment for incontinence, Approved September 1997

Prograf; Fujisawa Healthcare; Treatment for the prevention of kidney transplant rejection, Approved April 1997

Zenapax; Roche; Treatment to prevent rejection of kidney transplants, Approved December 1997

Drugs Approved in 1996

Cipro (ciprofloxacin HCl); Bayer; Treatment for cystitis, Approved April 1996

Elmiron (pentosan polysulfate sodium); IVAX; Treatment for interstitial cystitis, Approved October 1996

Eulexin (flutamide); Schering-Plough; Treatment for prostate cancer, Approved June 1996

Gemzar (gemcitabine HCL); Eli Lilly; Treatment for pancreatic cancer, Approved May 1996

Lupron Depot (leuprolide acetate for depot suspension); Abbott Laboratories; Treatment for advanced prostate cancer, Approved January 1996

Monurol; Forest Laboratories; Treatment for uncomplicated urinary tract infection, Approved December 1996

Nascobal Gel (Cyanocobalamin, USP); Questcor Pharmaceuticals; Treatment for vitamin B-12 deficiency, Approved November 1996

Seprafilm; Genzyme; Treatment for the reduction of scar tissue as a result of abdominal or pelvic surgery, Approved August 1996

Visipaque (iodixanol); Nycomed; Diagnostic contrast agent, Approved April 1996

Zoladex (10.8 mg goserelin acetate implant); AstraZeneca; Treatment for advanced prostate cancer, Approved January 1996

Drugs Approved in 1995

Caverject (alprostadil); Upjohn; Treatment for impotence, Approved on July 6, 1995